{'fraction_non_alphanumeric': 0.021844660194174758, 'fraction_numerical': 0.0048543689320388345, 'mean_word_length': 5.7073170731707314, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Platelet function after the single administration of buflomedil].

Earlier investigations have demonstrated that buflomedil, a substance which is successful in the clinical treatment of peripheral vascular disease, exerts an inhibitory effect on ADP-induced aggregation ex vivo and in vitro. In the presented study the effect of buflomedil on platelets is investigated. Clinically widely used platelet function tests were performed after a single oral dose of buflomedil (300 mg) to healthy volunteers. Again, an ex vivo inhibition of ADP-induced aggregation was confirmed. None of the other parameters examined was influenced by the administered drug, such as plasma thromboxane B2, the platelet proteins, the platelet sensitivity to antiaggregatory prostaglandins and the prostacyclin synthesis stimulating plasma factor.